MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced the addition of Nezam H. Afdhal, M.D., Chief of Hepatology, Director of Liver Center, Beth Israel Deaconess Medical Center and an Associate Professor of Medicine, Harvard School of Medicine; and Steven Fishbane, M.D., a distinguished nephrologist and widely published author in the field of renal anemia, to the Company’s Strategic Advisory Board (“SAB”).
